TickerFacts.

uniQure N.V. (QURE): Long-Term Debt

Annual figures by period end, from SEC filings.

$71.92M
As of 2025-12-31
-20.7%
3-year compound annual growth
+11.1%
5-year compound annual growth
$147.57M2017-12-31: $23.96M2018-12-31: $48.18M2019-12-31: $46.53M2020-12-31: $42.41M2021-12-31: $135.59M2022-12-31: $144.49M2023-12-31: $147.57M2024-12-31: $66.02M2025-12-31: $71.92M$71.92M
2017-12-31 Long-Term Debt (USD) 2025-12-31
Period endedLong-Term DebtChange YoYSource filing
2025-12-31$71.92M+8.9%2026-03-02, Balance as of period end
2024-12-31$66.02M-55.3%2025-02-27, Balance as of period end
2023-12-31$147.57M+2.1%2024-02-28, Balance as of period end
2022-12-31$144.49M+6.6%2023-02-27, Balance as of period end
2021-12-31$135.59M+219.7%2022-02-25, Balance as of period end
2020-12-31$42.41M-8.9%2021-03-01, Balance as of period end
2019-12-31$46.53M-3.4%2020-03-02, Balance as of period end
2018-12-31$48.18M+101.1%2019-02-28, Balance as of period end
2017-12-31$23.96Mn/a2018-03-14, Balance as of period end

Long-Term Debt at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedLong-Term DebtChange YoY
uniQure N.V. (QURE)2025-12-31$71.92M+8.9%
Arbutus Biopharma Corp (ABUS)2025-12-31$0n/a
CV Sciences, Inc. (CVSI)2025-12-31$1.65Mn/a
Tonix Pharmaceuticals Holding Corp. (TNXP)2024-12-31$8.65M-21.4%
Emmaus Life Sciences, Inc. (EMMA)2025-12-31$27.13M-6.3%
Precigen, Inc. (PGEN)2025-12-31$93.17Mn/a
BioAge Labs, Inc. (BIOA)2024-12-31$8.50Mn/a
Verastem, Inc. (VSTM)2024-12-31$40.72M+1.6%
Verrica Pharmaceuticals Inc. (VRCA)2025-12-31$0-100.0%

Compare QURE, ABUS, CVSI, TNXP side by side · Screen every company in Pharmaceutical Preparations ↗